Back to Search Start Over

The Utility of Intraluminal Therapies in Upper Tract Urothelial Carcinoma: A Narrative Review.

Authors :
Tyrrell, Jack
Chui, William
Kealey, Joshua
Sengupta, Shomik
Source :
Cancers. May2024, Vol. 16 Issue 10, p1931. 10p.
Publication Year :
2024

Abstract

Simple Summary: Tumours of the lining of the kidney and its drainage tube (the ureter) can be treated by surgery carried out through fine telescopes. There is an increased risk of tumours growing back after such surgery. One of the ways to reduce the risk is to put medications such as chemotherapy into the kidney to treat the lining and tumours on it. The location and structure of the kidney make this a difficult process. This article outlines the available and developing options for such treatment. Nephron sparing surgery (NSS) is considered for selected cases of upper tract urothelial carcinoma (UTUC) as it maintains renal function and avoids morbidity associated with radical nephroureterectomy (RNU). The appropriate selection of patients suitable for NSS without compromising oncological outcomes can sometimes be difficult, given the limitations of diagnostic modalities. Recurrence rates for UTUC can be as high as 36 to 54% after NSS. Intraluminal adjuvant therapy can be attempted following NSS to reduce recurrence, but delivery to the upper tract is more challenging than into the bladder. Bacillus Calmette-Guerin (BCG) and chemotherapy such as Mitomycin (MMC) have been administered via nephrostomy or ureteric catheter, which requires invasive/repeated instrumentation of the upper urinary tract. Drug delivery by reflux from bladder instillation along indwelling stents has also been tried but can potentially be unreliable. Recently, a gel formulation of mitomycin has been developed for the controlled exposure of the upper urinary tract to treatment over a number of hours. Drug-eluting stents to deliver chemotherapy to the upper urinary tract have been developed but have not yet entered clinical practice. Endoluminal phototherapy utilising an intravenous photosensitising agent is another novel approach that has recently been described. Intraluminal therapies may be beneficial in decreasing recurrence rates in UTUC, but currently have some limitations in their usage. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20726694
Volume :
16
Issue :
10
Database :
Academic Search Index
Journal :
Cancers
Publication Type :
Academic Journal
Accession number :
177490699
Full Text :
https://doi.org/10.3390/cancers16101931